548 news items
FDA Roundup: April 26, 2024
26 Apr 24
reference biologics, and treat illnesses like rheumatoid arthritis, inflammatory bowel disease, some cancers, psoriasis, diabetes, macular degeneration
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
AMST
HCA
HOOK
26 Apr 24
) application by the United States Food and Drug Administration (FDA) for HB 700. This product is a distinctive arenaviral therapeutic vaccine
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
MRK
25 Apr 24
cancer immunotherapy Keytruda largely drove the growth. Keytruda generated $6.95 billion in revenue during the quarter, up 20% from the year
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
-peptide formulation of Elicio's off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P, in patients with mKRAS-driven solid tumors
dg4bhnzc6z4hmujdhi6e6f6nw5pjbpdb9k
SNGX
25 Apr 24
thermostabilized Ebola vaccines MarVax™ and SuVax™
4bgf8xsam457nrau1imag5vorhk3etqdobtmbvkwnduac9z8eauh42
MRK
25 Apr 24
development of a new investigational, multi-valent HPV vaccine designed to provide broader protection against certain cancers and diseases caused
xk2bvzbn63r1hm x8gwgi
AZN
25 Apr 24
and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO plenary in June. We are also
581ykbsifq1b8sc76ysatr44rky7bxkra
25 Apr 24
the necessary pieces in place for some time, including discussions with the Hospital of the University of Pennsylvania, one of the leading cancer
vdsb6fur m6
25 Apr 24
Vaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from
drfqo3wemaongt1w iet5npuc03dzwqyrt0m39
IBRX
25 Apr 24
the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate
0hm670rx3ac 85zyqgw0
IOBT
24 Apr 24
biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced
58n093h9adpclqtsvt2yo9 210op
24 Apr 24
cancer cells. The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050